ImaginAb, Inc.

Industry · 7 registered clinical trials.

Status	Trial	Phase	Started
Terminated	CD8 Minibody Repeatability Study Melanoma, Renal Cell Carcinoma	Phase 2	2023-02-16
Active Not Recruiting	Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies Melanoma, Merkel Cell Carcinoma, Unspecified, Renal Cell Carcinoma	Phase 2	2021-12-09
Completed	⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors Positron-Emission Tomography, Metastatic Solid Tumors	Phase 2	2018-12-18
Completed	⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies	Phase 1	2017-06-19
Withdrawn	A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer Prostate Cancer	Phase 2	2015-03-01
Completed	Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre- Prostate Cancer	Phase 2	2015-01-01
Completed	Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer Metastatic Prostate Cancer	Phase 1 / Phase 2	2013-08-01